Tarek Ittobane
Papers
1
Total Citations
32
H-Index
1
About
Tarek Ittobane is a leading urologic surgeon and researcher whose work centers on optimizing surgical outcomes in kidney cancer treatment, with a particular focus on robotic partial nephrectomy. His major contributions challenge established practices in nephron-sparing surgery, most notably through the landmark EMERALD randomized controlled trial. This pivotal study, which has garnered significant attention with 32 citations, rigorously compared superselective ischemia against traditional renal artery clamping, demonstrating that the more technically demanding approach does not yield superior long-term renal function—a finding that has prompted surgeons to reconsider the risk-benefit calculus of ischemia techniques. Ittobane’s research is distinguished by its commitment to evidence-based surgery, directly informing clinical guidelines on how to best preserve kidney function while minimizing operative risks. His work is essential reading for any urologist or trainee navigating the complexities of partial nephrectomy, as it provides robust data to guide intraoperative decision-making. Through his rigorous trial design and clear clinical messaging, Ittobane has established himself as a thoughtful voice in the ongoing debate over surgical ischemia management.
Research Focus
Key Achievements
Top Papers
- 1